Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Apr 25, 2023 3:53pm
172 Views
Post# 35413172

Re: Re: Replicel Ownership

Re: Re: Replicel OwnershipRPINVESTOR1 posted:

"Not  too sure about the rules on a private takeover by insiders. Do they have a vote or do only the non-insiders get to vote? 
The interim order describes the process of calling and giving notice of the meeting of securityholders, the conduct of the meeting, and the level of approval by which securityholders of each class must approve the arrangement (generally 66% to 75%, depending on the province of incorporation of the target company and whether the holders of equity securities or creditors of the target will be statutorily required to vote respecting the plan of arrangement). The Court will almost always grant a right of dissent to each securityholder, providing securityholders entitled to vote at the meeting who oppose the proposed transaction to dissent and receive “fair value” for their voting securities as determined by a Court.

Also, has Replicel ever informed the shareholders as to the reason why the Chinese Company has not started the Phase 2 skin and tendon trials. They were very prompt in the construction their laboratory and then no further activity. Does their contract with Replicel contain a clause stating that the trials will not start until Replicel produces a dermal injector approved for sale on the market? "
No, we never hear about Yofoto.  I can only imagine how disappointed they are that the Dermal Injector has gone into a stall after all these years.  They will not be investing  another dime into Replicel until they market the device. 



 
 
<< Previous
Bullboard Posts
Next >>